Physician profile
Jeffrey Lee
NPI 1942642731
$3,012.33
in general payments reported to CMS, 2019-2025
24 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $39.24 · 2021: $145 · 2022: $337 · 2023: $726 · 2024: $665 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Travel and Lodging: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.67 |
| Travel and Lodging | $166.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $485.37 | 2020-2025 | |
| Philips North America LLC | $274.12 | 2022-2025 | (5044) Mcot, Extended Holter, Mcot |
| Siemens Medical Solutions USA, INC. | $273.50 | 2025 | |
| Amgen INC. | $212.87 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $201.45 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $200.09 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.41 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $170.38 | 2019-2025 | Watchman Flx, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.33 | 2023-2025 | Lifevest |
| Pfizer INC. | $160.72 | 2021-2025 | |
| Abbott Laboratories | $122.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $79.01 | 2020-2025 | Farxiga, Wainua |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Impulse Dynamics (USA) INC. | $60.21 | 2023-2025 | Optimizer, Optimizer |
| Kestra Medical Technology Services, INC. | $57.46 | 2022-2023 | Assure Wcd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $50.03 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $49.40 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $46.26 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $38.08 | 2024 | Amvuttra |
| Novo Nordisk INC | $35.69 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $31.13 | 2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $21.85 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.00 | 2025 | |
| Glaxosmithkline, LLC. | $17.44 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.